肾移植和肝移植合并丙型肝炎受者中当前直接抗病毒方案的安全性和疗效:HCV-TARGET研究结果
HCV-TARGET多中心前瞻性观察队列纳入2014年1月1日至2016年2月15日接受直接抗病毒方案治疗的443例肝移植、肾移植及肝肾双移植受者,412例可评估12周持续病毒学应答(SVR12),395例(95.9%)达到SVR12,肝移植、肾移植、肝肾双移植受者分别为96.6%、94.5%、90.9%;利巴韦林不影响SVR率,移植物排斥罕见。
要点
- 肝移植、肾移植、肝肾双移植受者SVR12分别为96.6%、94.5%、90.9%。
- 利巴韦林未影响SVR率。
- 急性排斥6例(肾移植2例、肝移植4例),移植物排斥罕见。
核心结论
- 在大规模前瞻性观察队列中,索磷布韦/来迪派韦、奥比他韦/帕利瑞韦/利托那韦+达萨布韦及索磷布韦联合达拉他韦方案在肝移植、肾移植和肝肾双移植受者中有效且安全。
- 利巴韦林不影响SVR,移植物排斥罕见。
研究设计与样本
- HCV-TARGET数据库为多中心、纵向临床诊疗治疗队列。
- 纳入2014年1月1日至2016年2月15日期间接受直接抗病毒方案治疗的肝移植、肾移植及肝肾双移植受者443例(肾移植60例、肝移植347例、肝肾双移植36例)。
- 42%有肝硬化,54%既往抗病毒治疗失败。
主要发现
- 412例可评估SVR12,395例(95.9%)达到SVR12;肝移植、肾移植、肝肾双移植受者分别为96.6%、94.5%、90.9%。
- 基因1型占87%(其中1a型52%、1b型27%、1型未分亚型8%);索磷布韦/来迪派韦±利巴韦林占85%,索磷布韦+达拉他韦±利巴韦林占9%,奥比他韦/帕利瑞韦/利托那韦+达萨布韦±利巴韦林占6%。
- 利巴韦林未影响SVR率,更常用于BMI较高、估算肾小球滤过率较高和肌酐较低者。
- 女性、基线白蛋白≥3.5 g/dL、基线总胆红素≤1.2 mg/dL、无肝硬化及无肝失代偿预测SVR12。
- 急性排斥6例(肾移植2例、肝移植4例),其中4例发生在丙型肝炎病毒治疗期间、2例在治疗停止后。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Data outside of clinical trials with direct-acting antiviral regimens with or without ribavirin as treatment of chronic hepatitis C virus in solid organ transplant recipients are limited. Liver transplant (LT), kidney transplant (KT), and dual liver kidney (DLK) transplant recipients from the Hepatitis C Therapeutic Registry and Research Network database, a multicenter, longitudinal clinical care treatment cohort, treated with direct-acting antiviral regimens between January 1, 2014, and February 15, 2016, were included to assess safety and efficacy. Included were 443 posttransplant patients (KT = 60, LT = 347, DLK = 36); 42% had cirrhosis, and 54% had failed prior antiviral therapy. Most had genotype (GT) 1 (87% with 52% GT1a, 27% GT1b, and 8% GT1 no subtype) and were treated with sofosbuvir (SOF)/ledipasvir ± ribavirin (85%) followed by SOF + daclatasvir ± ribavirin (9%) and ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin (6%). Rates of sustained virologic response (SVR) at 12 weeks were available on 412 patients, and 395 patients (95.9%) achieved SVR at 12 weeks: 96.6%, 94.5%, and 90.9% among LT, KT, and DLK transplant recipients, respectively. Ribavirin did not influence SVR rates and was more often used in those with higher BMI, higher estimated glomerular filtration rate and lower creatinine. Female gender, baseline albumin ≥3.5 g/dL, baseline total bilirubin ≤1.2 mg/dL, absence of cirrhosis, and hepatic decompensation predicted SVR at 12 weeks. Six episodes of acute rejection (n = 2 KT, 4 LT) occurred, during hepatitis C virus treatment in 4 and after cessation of treatment in 2. CONCLUSION: In a large prospective observational cohort study, direct-acting antiviral therapy with SOF/ledipasvir, ombitasvir/paritaprevir/ritonavir + dasabuvir, and SOF plus daclatasvir was efficacious and safe in LT, KT, and DLK transplant recipients; ribavirin did not influence SVR, and graft rejection was rare. (Hepatology 2017;66:1090-1101).
引用
- Saxena V, Khungar V, Verna EC, et al. Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-TARGET study. Hepatology. 2017. PMID: 28504842. doi:10.1002/hep.29258
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。